Skip to main content
ODTX logo

Odyssey Therapeutics, Inc.

ODTXNASDAQHealthcareBiotechnology

$17.57Today:- (-)

As of Oct 15, 2026 close

Market cap
$531.97M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$15.10$29.05
Volume (live)
-
Avg. volume (3M)
361.31K

Odyssey Therapeutics (ODTX) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Odyssey Therapeutics used $129.47M of cash in operating activities and spent $1.23M on capital expenditures. That left free cash flow of −$130.70M.

Odyssey Therapeutics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Odyssey Therapeutics, Inc. (ODTX) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022
Period endingDec 2025Dec 2024Dec 2023Dec 2022
Operating Activities
Net Income-148.65-129.32-125.94-124.67
Depreciation & Amortization4.915.194.912.76
Stock Based Compensation14.328.696.265.52
Change in Working Capital-4.73-3.310.90-0.54
Change in Accounts Payable2.06-1.702.243.27
Change in Other Working Capital-0.615.73-0.2617.09
Other Operating Activities-0.615.731.1517.09
Net Cash from Operating Activities-129.47-117.47-112.73-99.84
Investing Activities
Capital Expenditures-1.23-0.76-5.06-13.03
Purchases of Investments-208.97-52.61-238.11-
Sales/Maturities of Investments105.90150.1678.12-
Other Investing Activities0.36---
Net Cash from Investing Activities-103.9496.78-165.02-13.03
Financing Activities
Common Stock Issued3.190.510.260.08
Other Financing Activities212.46-1.01--
Net Cash from Financing Activities215.6526.9892.08182.72
Summary
Effect of Forex Changes on Cash0.320.050.01-0.02
Net Change in Cash-17.456.34-185.6769.83
Cash at Beginning of Period62.3556.00241.67171.85
Cash at End of Period44.9062.3556.00241.67
Free Cash Flow-130.70-118.24-117.78-112.87

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Odyssey Therapeutics Cash Flow

What is Odyssey Therapeutics's free cash flow?

Odyssey Therapeutics had negative free cash flow of $130.70M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$129.47M minus $1.23M of capital expenditures.

How much does Odyssey Therapeutics spend on capital expenditures?

Odyssey Therapeutics spent $1.23M on capital expenditures in fiscal 2025, compared with $764.00K a year earlier.

Does Odyssey Therapeutics pay dividends or buy back shares?

Odyssey Therapeutics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition